Prediction of advanced fibrosis in nonalcoholic fatty liver disease: An enhanced model of BARD score

Gut and Liver

Volumn 7, Issue 3, 2013, Pages 323-328

  Lee, Tae Hoon ^a   Han, Seung Hye ^b   Yang, Ju Dong ^c   Kim, Donghee ^c,d   Ahmed, Monjur ^e  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MAYO CLINIC   (United States)

^d Seoul National University Hospital   (South Korea)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

International normalized ratio; Liver cirrhosis; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BARD SCORE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; RISK ASSESSMENT;

EID: 84879339004     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.3.323     Document Type: Article

References (19)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395. (Pubitemid 39657013)
2. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55:560-578.
3. Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977-986. (Pubitemid 36560797)
4. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:877-883.
5. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462.
6. Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007;56:1330-1331. (Pubitemid 47300449)
7. Yoneda M, Mawatari H, Fujita K, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40:371-378.
8. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468. (Pubitemid 40110657)
9. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008;47:332-342. (Pubitemid 351171070)
10. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007;42:242-247. (Pubitemid 46398863)
11. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123. (Pubitemid 30346988)
12. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713. (Pubitemid 39575849)
13. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325. (Pubitemid 43980111)
14. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460. (Pubitemid 351280713)
15. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447.
16. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. (Pubitemid 46631552)
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474. (Pubitemid 29420675)
18. Moore C. SAS macro CVLR (cross-validation for logistic regression) [Internet]. Athens: University of Georgia; 2000 [cited 2010 Nov 16]. Available from: http://ctmoore.myweb.uga.edu/prof/CVLRnotes.htm.
19. Centers for Disease Control and Prevention (CDC). Estimated county-level prevalence of diabetes and obesity: United States, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1259-1263.